Double-Blind, Randomized, Active-Controlled Comparison of the Immunogenicity and Safety of Flublok Quadrivalent Versus IIV4 in Healthy, Medically Stable Adults 18-49 Years of Age

Trial Profile

Double-Blind, Randomized, Active-Controlled Comparison of the Immunogenicity and Safety of Flublok Quadrivalent Versus IIV4 in Healthy, Medically Stable Adults 18-49 Years of Age

Completed
Phase of Trial: Phase III

Latest Information Update: 09 Sep 2017

At a glance

  • Drugs Influenza virus RIV4 vaccine-(FluBlok Quadrivalent) (Primary) ; Influenza virus vaccine
  • Indications Influenza virus infections
  • Focus Pharmacodynamics; Registrational
  • Sponsors Protein Sciences Corporation
  • Most Recent Events

    • 09 Sep 2017 Results published in the Journal of Infectious Diseases.
    • 26 Oct 2015 Status changed from active, no longer recruiting to completed, according to ClinicalTrials.gov record.
    • 09 Dec 2014 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top